InterCure Ltd.
NASDAQ:INCRDrug Manufacturers - Specialty & Generic
-$0.04 today
- Market cap
- $51.63M
- Beta
- 0.57
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.64
Volume 0.01M
Average 0.04M
INCR Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
InterCure Ltd.NASDAQ: INCR
Research & Development · Q2 FY2025 · quarter ended Jun 2025
Research & development dips below year-ago levels
Q2 FY2025 research & development of ₪95.5K fell 12.8% year over year, behind the +10.0% change in trailing-twelve-month research & development. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -14.9% a year.
Context
- Research & development amounted to 0.1% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -12.8% toward the trailing-twelve-month pace of +10.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
ILS · from the income statement
- Latest · FY2025
- 390K ILS
- Year-over-year change
- -5.8%
- 4-year CAGR
- -25.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 390K | -5.8% |
| FY2024 | 2024-12-31 | 414K | +6.7% |
| FY2023 | 2023-12-31 | 388K | -38.6% |
| FY2022 | 2022-12-31 | 632K | -48.8% |
| FY2021 | 2021-12-31 | 1.24M | — |
Research & Development vs competitors
How INCR compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +10.0% is the 2nd highest of 9, against a peer median of -33.4%.
- Research & development amounts to 0.2% of revenue for INCR, versus a peer median of 24.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $63.14M USD | -22.5% | -19.3% | 26.6% | |
| LTM Mar 2026 | $48.2M USD | -55.0% | -0.4% | — | |
| LTM Mar 2026 | $37.7M USD | -3.9% | — | 958.2% | |
| LTM Mar 2026 | CA$15.22M CAD | +22.5% | +0.1% | — | |
| LTM Mar 2026 | $8.57M USD | -44.2% | -9.8% | — | |
| LTM Mar 2026 | $8.51M USD | -76.4% | -55.5% | 12.9% | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | CA$4.56M CAD | +1.7% | -13.6% | 24.8% |
| LTM Mar 2026 | $1.71M USD | -51.6% | — | 1.7% | |
| LTM Jun 2025 | ₪386K ILS | +10.0% | -14.9% | 0.2% | |
| Peer median (excluding INCR) | — | -33.4% | -11.7% | 24.8% | |
Competitors are the stored peer set for INCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 219.68M | 388.68M | 355.55M | 238.85M | 270.2M |
| Cost of Revenue | 128.55M | 233.6M | 250.46M | 208.61M | 237.02M |
| Gross Profit | 91.13M | 155.08M | 105.1M | 30.23M | 33.18M |
| Gross Margin | 41.5% | 39.9% | 29.6% | 12.7% | 12.3% |
| Research & Development | 1.24M | 632K | 388K | 414K | 390K |
| Selling, General & Admin | 53.46M | 97.32M | 86.24M | 84.63M | 80.41M |
| Operating Expenses | 62.95M | 104.46M | 146.66M | 97.44M | 26.45M |
| Depreciation & Amortization | 7.39M | 11.7M | 13.17M | 15.37M | 17.15M |
| EBITDA | 31.17M | 70.23M | (23.9M) | (51.31M) | (7.29M) |
| EBITDA Margin | 14.2% | 18.1% | -6.7% | -21.5% | -2.7% |
| Operating Income | 28.19M | 50.63M | (41.57M) | (67.21M) | 6.73M |
| Operating Margin | 12.8% | 13.0% | -11.7% | -28.1% | 2.5% |
| Interest Income | 130K | 844K | 4.55M | 2.7M | 1.56M |
| Interest Expense | 5.05M | 14.69M | 24.22M | 20.65M | 19.66M |
| Other Income / Expenses | (9.45M) | (6.79M) | (19.72M) | (20.12M) | (50.84M) |
| Income Before Tax | 18.74M | 43.84M | (61.29M) | (87.32M) | (44.1M) |
| Pre-Tax Margin | 8.5% | 11.3% | -17.2% | -36.6% | -16.3% |
| Income Tax Expense | 11.44M | 93K | 2.25M | (14.53M) | (7.32M) |
| Net Income | 4.69M | 44.82M | (61.96M) | (67.8M) | (35.71M) |
| Net Margin | 2.1% | 11.5% | -17.4% | -28.4% | -13.2% |
| EPS (Basic) | 0.12 | 0.99 | (1.36) | (1.42) | (0.63) |
| EPS (Diluted) | 0.11 | 0.99 | (1.36) | (1.42) | (0.63) |
| Weighted Avg Shares | 38.49M | 45.35M | 45.56M | 47.77M | 56.8M |
| Weighted Avg Shares (Diluted) | 40.84M | 45.35M | 45.57M | 47.77M | 56.8M |
InterCure Ltd.
NASDAQ:INCR
Intrinsic Alpha fair value
Locked
Current Price
$3.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.